starogyn 15 mg g vaginal cream - search results

Singapore - English - HSA (Health Sciences Authority)

premarin vaginal cream

pfizer private limited - oestrogens (conjugated) - cream - 0.625 mg/g - oestrogens (conjugated) 0.625 mg/g

premarin vaginal cream

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - estrogens conjugated - cream - estrogens conjugated 0.625 mg/g - sex hormones and modulators of the genital system

Canada - English - Health Canada

premarin vaginal cream

pfizer canada ulc - conjugated estrogens - cream - 0.625mg - conjugated estrogens 0.625mg - estrogens

Australia - English - Department of Health (Therapeutic Goods Administration)

ovestin 1mg/g cream tube

aspen pharmacare australia pty ltd - estriol, quantity: 1 mg/g - cream - excipient ingredients: sodium hydroxide; stearyl alcohol; lactic acid; cetyl esters wax; purified water; chlorhexidine hydrochloride; sorbitan monostearate; octyldodecanol; glycerol; polysorbate 60; cetyl alcohol - indications as at 18 december 2001. vulvo-vaginal complaints due to oestrogen deficiency associated with the climacteric and the postmenopause or after ovariectomy: atrophic vaginitis. puritis vulvae. dyspareunia due to vulvo-vaginal atrophy. as auxiliary therapy in the treatment of vaginal infections. as pre-operative therapy for vulvo-vaginal surgery and during subsequent convalescence. ulcers in the case of prolapse of the uterus or vagina. to avoid misinterpretation of a cytological smear.

United States - English - NLM (National Library of Medicine)

premarin vaginal- conjugated estrogens cream

wyeth pharmaceuticals llc, a subsidiary of pfizer inc. - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg in 1 g - premarin vaginal cream therapy should not be used in women with any of the following conditions: premarin vaginal cream should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. premarin vaginal cream should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectable amounts of estrogens have been identified in the breast milk of women receiving estrogen therapy. caution should be exercised when premarin vaginal cream is administered to a nursing woman. premarin vaginal cream is not indicated in children. clinical studies have not been conducted in the pediatric population. there have not been sufficient numbers of geriatric women involved in clinical studies utilizing premarin vaginal cream to determine whether those over 65 years of age differ from younger subjects in their response to premarin vaginal cream. the women's health initiative studies in the whi estrogen-alone substudy (daily ce [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see warnings and precautions (5.2), and clinical studies (14.2)] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see warnings and precautions (5.2, 5.3), and clinical studies (14.2)] . the women's health initiative memory study in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.4), and clinical studies (14.3)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see warnings and precautions (5.4), and clinical studies (14.3)] . the effect of renal impairment on the pharmacokinetics of premarin vaginal cream has not been studied. the effect of hepatic impairment on the pharmacokinetics of premarin vaginal cream has not been studied.